

Press Release

Belgium, Gentbrugge October 13, 2008

TRINEAN announces closing of a 3,5 million Euro funding round.

Trinean NV, an innovative player in the sector of molecular instrumentation, today announced the closure of a 3,5 million € round of financing. The round was co-lead by new investor Vesalius Biocapital and existing investor Capital-E.

Trinean (www.trinean.com) is a spin-off of the University of Ghent (Intec) and IMEC. The company develops and markets the first nanoliter spectrophotometer with corresponding micro fluidic consumables allowing full spectrum UV/VIS spectroscopic measurements in droplets of liquids between 0,5 and 2,5 µL in a microplate format in a very fast and automated way.

The initial target application is the determination of DNA/RNA concentrations in small sample volumes. This is of great importance to the biotech industry where today valuable DNA/RNA material has to be sacrificed in order to measure these concentrations, and where test procedures are time consuming.

Next to DNA/RNA quantification, other applications will also be targeted such as ADME testing, protein concentration measurements, enzymology, nephelometry and clinical diagnostics.

The investment round will allow Trinean to start production, bring its products to the market and develop new applications.

The company is run by a senior management team consisting of Jan Boon (COO), (ex- Elscolab, Thermo Life Sciences, Flow Laboratories , Pharmacia Diagnostics....) and Prof. Marc Zabeau (CEO) (ex- Plant Genetic Systems, Helix, KeyeGene, Genscope, Methexis...)

For further information please contact:

Jan Boon, COO Dulle Grietlaan, 17/3 B-9050 Gentbrugge . Tel.: 09 272 7535
jan.boon@trinean.com

About Trinean

Trinean is a developer and producer of nanoliter spectrophotometers and consumables for the scientific market. The use of a **unique polychromatic spectroscopy system** combined with **microfluidic chips** in **microplate format**, provides the world-wide scientists a gain of time, accuracy and costly samples and reagents, which is of high importance to the biotech applications. More information can be obtained at www.trinean.com .

About Vesalius Biocapital

www.vesaliusbiocapital.com

About Capital-E

Capital-E is an early stage venture fund focused exclusively on micro- and nano-electronics related ventures in Europe. We help initiate and grow businesses with venture capital, sound advice and access to a broad industry network and

research ecosystem. Through its entrenched relationship with IMEC, the largest independent research centre in micro- and nano-electronics in Europe, the fund and its ventures can directly rely on the support of over 1500 specialised scientists and engineers, as well as leverage on IMEC's 500+ worldwide industrial partners such as NXP, Infineon, STMicroelectronics, Intel, Panasonic, Texas Instruments, Samsung and TSMC to speed-up the process of market entry. The fund is managed by an independent team with a balanced mix of entrepreneurial, industrial and VC experience. More information can be obtained at www.capital-e.com .